Pharmacokinetic/pharmacodynamic (PK/PD) Characteristics of Veliparib with and without Temozolomide in Patients with Hematological Malignancies

被引：0
|
作者：
Singh, Renu [1 ]
Gopalakrishnan, Mathangi [1 ]
Kiesel, Brian F. [2 ]
Greer, Jacqueline M. [3 ]
Karp, Judith E. [3 ]
Gojo, Ivana [3 ]
Gobburu, Jogarao [1 ]
Rudek, Michelle A. [3 ]
Beumer, Jan H. [2 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-47
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [21] A phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies
    Ottmann, OG
    Deangelo, DJ
    Stone, RM
    Pfeifer, H
    Lowenberg, B
    Atadja, P
    Peng, B
    Scott, JW
    Dugan, M
    Sonneveld, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 201S - 201S
  • [22] Phase 1, pharmacokinetic (PK) and, pharmacodynamic (PD) study of intravenous alvespimycin (KOS-1022) in patients with refractory hernatological malignancies.
    Lancet, Jeffrey
    Baer, Maria R.
    Gojo, Ivana
    Burton, M.
    Quinn, M.
    Tighe, S. M.
    Bhalla, Kapil
    Kersey, K.
    Wells, S.
    Zhong, Z.
    Sadler, B.
    Albitar, Maher
    Johnson, Robert
    Hannah, Alison
    BLOOD, 2006, 108 (11) : 555A - 555A
  • [23] Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats
    Kobuchi, Shinji
    Katsuyama, Yosuke
    Ito, Yukako
    XENOBIOTICA, 2020, 50 (02) : 146 - 153
  • [24] Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses to Support Olaparib Tablet Approval in Ovarian Cancer
    Xu, Hongmei
    Zhou, Diansong
    Li, Jianguo
    Berges, Alienor
    Bui, Khanh
    Milenkova, Tsveta
    Tomkinson, Helen
    Al-Huniti, Nidal
    Learoyd, Maria
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S36 - S36
  • [25] RO4929097 IN COMBINATION WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED MALIGNANT GLIOMA (MG): A PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) STUDY
    Omuro, Antonio
    Beal, Kathryn
    Ivy, Percy
    Gutin, Philip
    Wu, Nian
    Kaley, Thomas
    Karimi, Sasan
    DeAngelis, Lisa
    Pentsova, Helena
    Nolan, Craig
    Grommes, Christian
    Chan, Timothy
    Mathew, Raj
    Droms, Leif
    Shimizu, Fumiko
    Tabar, Viviane
    NEURO-ONCOLOGY, 2012, 14 : 80 - 80
  • [26] Secondary hematological malignancies associated with temozolomide in patients with glioma
    Momota, Hiroyuki
    Narita, Yoshitaka
    Miyakita, Yasuji
    Shibui, Soichiro
    NEURO-ONCOLOGY, 2013, 15 (10) : 1445 - 1450
  • [27] In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
    Xia Xiao
    Jian Sun
    Yi Chen
    Rui-Juan Huang
    Ting Huang
    Guilin Gary Qiao
    Yu-Feng Zhou
    Ya-Hong Liu
    BMC Veterinary Research, 11
  • [28] Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine.
    Maenpaa, J
    Wrighton, S
    Bergstrom, R
    Cerimele, B
    Tatum, D
    Hatcher, B
    Callaghan, JT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PIV8 - PIV8
  • [29] Pharmacokinetic/pharmacodynamic/(PK/PD) model for abciximab in healthy subjects.
    Abernethy, DR
    Pezzullo, J
    Freedman, J
    Mascelli, MA
    Frederick, B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 141 - 141
  • [30] HYDROMORPHONE BIOAVAILABILITY AND PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    STILLMAN, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 162 - 162
12345